The Localization of Label-Retaining Cells in Eccrine Glands

    Motonobu Nakamura, Y. Tokura
    TLDR Stem cells in eccrine glands could be used for regenerative medicine.
    The study investigated the localization of label-retaining cells, which are indicative of stem cells, in mouse and human eccrine glands. Using BrdU pulse-chase experiments, researchers found that these cells were present in the secretory gland and coiled duct of eccrine glands, but not in the straight or intraepidermal ducts. In human skin transplanted onto mice, label-retaining cells expressed keratin 15, a marker for stem cells, in the secretory segment. The distribution of these cells was scattered, similar to patterns seen in mammary glands. This suggested that stem cells in eccrine glands could potentially be used in regenerative medicine. The study involved five newborn BALB/c Cr Slc mice and human skin from five patients.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 557 results

      community I had claude create a protocol only using fda approved drugs.

      in Research/Science  1 upvotes 3 days ago
      A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

      community PP405 could be released before GTA 6

      in Chat  133 upvotes 1 month ago
      PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

      community What 3 months without fin& min does😔

      in Progress Pictures  261 upvotes 1 year ago
      Stopping minoxidil and finasteride for three months caused significant hair loss. The user resumed treatment with 2.5mg oral minoxidil and 0.6mg finasteride and plans to update on progress in three months.

    Related Research

    5 / 5 results